Phase I Open Label Clinical Trial to Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment
Latest Information Update: 04 Dec 2024
At a glance
- Drugs GXIPC 1 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 03 Jun 2024 Planned End Date changed from 30 Oct 2023 to 30 Dec 2024.
- 03 Jun 2024 Planned primary completion date changed from 30 Oct 2022 to 30 Dec 2024.
- 03 Jun 2024 Status changed from recruiting to active, no longer recruiting.